Abbreviations: Xeloda: capecitabine; AC: anthracycline and cyclophosphamide; VEGF mAb: vascular endothelial growth factor monoclonal Antibody; TBD: to be determined.
R&D
R&D Pipeline
Building balanced and differentiated pipeline covering products from early- to late-stage through both in-house development and in-licensing.
.
Assets
Indication
Combo
Development area
Pre-clinical
Phase I
Phase II
Phase III
NDA
Commercial
Rights
Utidelone Injection
Advanced breast cancer
Xeloda
CN
GlobalXeloda
Global
GlobalAdvanced non-small cell lung cancer
Monotherapy
CN
GlobalMonotherapy
Global
GlobalBreast cancer neoadjuvant
AC
CN
GlobalSolid tumors
Monotherapy／PD-1
CN
GlobalBreast cancer brain metastasis
Xeloda
US
GlobalLung cancer brain metastasis
VEGF mAb
CN
GlobalGlioblastoma
VEGF mAb
CN & US
GlobalUtidelone Capsule
Solid tumors
Monotherapy
US
GlobalMonotherapy／Xeloda
CN
GlobalAdvanced breast cancer
Xeloda
CN
GlobalAdvanced gastric and esophageal cancers
PD-1
CN & US
GlobalAdvanced liver cancer
PD-1
CN
GlobalAdvanced ovarian cancer
VEGF mAb
CN & US
GlobalUtidelone nano-injection
Solid tumors
TBD
CN
GlobalUtidelone antibody-drug conjugate
Solid tumors
TBD
Global
GlobalBG22
Solid tumors
TBD
Global
GlobalBG18
Solid tumors
TBD
Global
GlobalBG44
Solid tumors
TBD
Global
Global